Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Ketone Monitoring in T1D Using Empagliflozin
NCT07848204Phase 1Completed
- Sponsor
- McGill University Health Centre
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in type 1 diabetes mellitus (T1D), sponsored by McGill University Health Centre. Primary endpoint: Number of ketone events above thresholds at 17 weeks. Started Jan 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07848204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848204.